Financial News

Financial Report: Bristol-Myers Squibb

Eliquis, Opdivo sales offset decline in established brands

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb 1Q Revenues: $5.9 Billion (+14%) 1Q Earnings: $1.7 billion (+15%) Comments: Eliquis sales were up 28% in the quarter to $1.9 billion. Opdivo sales were up 19% to $1.8 billion. Orencia sales were $640 million, up 8%. Yervoy sales were up 54% to $354 million. Baraclude sales were down 37% to $141 million. Other established brands sales were down 21% to $487 million. U.S. revenues increased 24% to $3.4 billion in the quarter. International revenues increased 2%. In April, th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters